Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label study of HTMC0658 tablets for chronic rhinosinusitis without nasal polyps
CTR20253465Phase 2Active
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HTMC0658 in chronic rhinosinusitis (CRS), sponsored by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. Primary endpoint: Change from baseline in Lund-MacKay score on sinus CT. Started Sep 2025; status: active.
02
Drugs
HTMC0658
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on CTR20253465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253465.